[{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\u003Cdiv id=\u0022republish_modal_form\u0022\u003E\u003Cform class=\u0022modal-form-example-modal-form ecl-form\u0022 data-drupal-selector=\u0022modal-form-example-modal-form\u0022 action=\u0022\/en\/article\/modal\/7251\u0022 method=\u0022post\u0022 id=\u0022modal-form-example-modal-form\u0022 accept-charset=\u0022UTF-8\u0022\u003E\u003Cp\u003EHorizon articles can be republished for free under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.\u003C\/p\u003E\n \u003Cp\u003EYou must give appropriate credit. We ask you to do this by:\u003Cbr \/\u003E\n 1) Using the original journalist\u0027s byline\u003Cbr \/\u003E\n 2) Linking back to our original story\u003Cbr \/\u003E\n 3) Using the following text in the footer: This article was originally published in \u003Ca href=\u0027#\u0027\u003EHorizon, the EU Research and Innovation magazine\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003ESee our full republication guidelines \u003Ca href=\u0027\/horizon-magazine\/republish-our-stories\u0027\u003Ehere\u003C\/a\u003E\u003C\/p\u003E\n \u003Cp\u003EHTML for this article, including the attribution and page view counter, is below:\u003C\/p\u003E\u003Cdiv class=\u0022js-form-item form-item js-form-type-textarea form-item-body-content js-form-item-body-content ecl-form-group ecl-form-group--text-area form-no-label ecl-u-mv-m\u0022\u003E\n \n\u003Cdiv\u003E\n \u003Ctextarea data-drupal-selector=\u0022edit-body-content\u0022 aria-describedby=\u0022edit-body-content--description\u0022 id=\u0022edit-body-content\u0022 name=\u0022body_content\u0022 rows=\u00225\u0022 cols=\u002260\u0022 class=\u0022form-textarea ecl-text-area\u0022\u003E\u003Ch2\u003EAlpacas and antibodies: How scientists hope to stop coronavirus in its tracks\u003C\/h2\u003E\u003Cp\u003EResearchers at the \u003Ca href=\u0022https:\/\/ki.se\/en\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EKarolinska Institute\u003C\/a\u003E in Stockholm, Sweden, are optimistic that at least one of the \u003Ca href=\u0022https:\/\/www.who.int\/who-documents-detail\/draft-landscape-of-covid-19-candidate-vaccines\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003E124 vaccines\u003C\/a\u003E in the pipeline will succeed. However, a vaccine needs to be delivered to everyone, and scaling to more than 7 billion doses is extremely challenging. So they have set their research sights on a more accessible goal: \u2018neutralising\u2019 antibodies that kill an infection after it has taken hold.\u003C\/p\u003E\u003Cp\u003EThe project \u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/id\/101003653\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003ECoroNAb\u003C\/a\u003E was established in mid-February when there were 1,000 known deaths from Covid-19 in the world. \u2018Containing the spread of the virus is not our primary objective \u2013 that ship has sailed,\u2019 said Dr Benjamin Murrell, assistant professor at the Department of Microbiology, Tumor and Cell Biology at the \u003Ca href=\u0022https:\/\/ki.se\/en\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EKarolinska Institute\u003C\/a\u003E. \u2018Our aim is to find therapeutics to stop the progression of disease within a patient.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ETherapeutics \u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EThese therapeutics will take the form of antibodies that are infused into a patient through a syringe. When someone is infected with the new SARS-CoV-2 coronavirus, they typically mount an antibody response against it, and in most cases these antibodies contribute to clearing the virus. However, infection-fighting antibodies produced in a lab can also be introduced into the body, resulting in passive immunisation.\u003C\/p\u003E\u003Cp\u003ESo what differentiates a vaccine from imported antibodies?\u003C\/p\u003E\u003Cp\u003EVaccines are given to people when they are well, prompting them to develop their own antibodies, whereas antibody therapy is administered when an infection has taken hold and a patient is struggling to mount their own immune response.\u003C\/p\u003E\u003Cp\u003EMonoclonal antibodies (mAbs) \u2013 that is, antibodies that are identical clones of one another \u2013 have emerged over the past few decades as effective therapies for various medical conditions, including cancers and autoimmune disorders. Increasingly, they are also considered a major medical tool to fight severe viral infections \u2013 such as Covid-19 \u2013 though to date, \u003Ca href=\u0022https:\/\/en.wikipedia.org\/wiki\/Palivizumab\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003Eonly one mAb been approved\u003C\/a\u003E for this purpose. Many more are in clinical trials, \u003Ca href=\u0022https:\/\/www.nature.com\/articles\/nm.4268\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003Eincluding one\u003C\/a\u003E that Dr Murrell has been working on.\u003C\/p\u003E\u003Cp\u003EAt what stage of an infection, exactly, a coronavirus patient would be treated with mAbs remains to be seen. \u2018This will need to be studied in animal models, or directly in human trials,\u2019 said Dr Murrell, who is coordinating the CoroNAb project together with partners in Denmark, Switzerland, and the UK.\u003C\/p\u003E\u003Cp\u003E\u2018Maybe you can treat someone with monoclonal antibody therapy late in infection and still stop deterioration, but perhaps not,\u2019 he said.\u003C\/p\u003E\u003Cp\u003EThe CoroNAb team at the Karolinska Institute is creating mAbs from animals. An animal is given a specific viral antigen (the molecules that interact with a body\u2019s antibodies) and an immune response is provoked, leading to some of the animal\u2019s immune cells producing antibodies. The cells harbouring these antibodies are then isolated and the genetic sequence of the antibody is cloned from each cell into a circular form of DNA that allows the antibodies to be produced in the lab.\u003C\/p\u003E\u003Cp\u003E\u003Cblockquote class=\u0022tw-text-center tw-text-blue tw-font-bold tw-text-2xl lg:tw-w-1\/2 tw-border-2 tw-border-blue tw-p-12 tw-my-8 lg:tw-m-12 lg:tw--ml-16 tw-float-left\u0022\u003E\n \u003Cspan class=\u0022tw-text-5xl tw-rotate-180\u0022\u003E\u201c\u003C\/span\u003E\n \u003Cp class=\u0022tw-font-serif tw-italic\u0022\u003E\u2018Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.\u2019\u003C\/p\u003E\n \u003Cfooter\u003E\n \u003Ccite class=\u0022tw-not-italic tw-font-normal tw-text-sm tw-text-black\u0022\u003EDr Benjamin Murrell, Karolinska Institute in Stockholm, Sweden\u003C\/cite\u003E\n \u003C\/footer\u003E\n\u003C\/blockquote\u003E\n\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EAlpacas\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EThe Stockholm team is focusing its research efforts on mice, rhesus macaques and alpacas. Alpacas are camelids (like camels and llamas) producing particularly interesting antibody fragments, known as \u2018single domain\u2019 antibodies, which allow for fast antibody discovery and large-scale antibody production, which is why they are favoured by the CoroNAb team.\u003C\/p\u003E\u003Cp\u003EOne month into the project, these mammals have been injected with lab-created variants of the coronavirus\u2019s spike proteins, and preliminary indications suggest that all animal groups are responding well. Mining the alpaca antibody repertoire is currently underway. Over the next few weeks, the researchers will be testing the neutralising activity of the produced antibodies against SARS-CoV-2.\u003C\/p\u003E\u003Cp\u003EDr Murrell said: \u2018The coming weeks are both critical and uncertain. Depending on these first results, we\u2019ll either get lucky, or we might have to take a few steps back and repeat.\u2019\u003C\/p\u003E\u003Cp\u003EDespite all the unknowns, Dr Murrell is confident that neutralising antibodies will emerge from this research. \u2018We will make something work,\u2019 he said. The question is, will an effective antibody discovered by the CoroNAb team become a useful addition to Europe\u2019s arsenal of SARS-CoV-2 treatments? Labs around the world are chasing the same prize, working night and day to identify effective antibodies against Covid-19, with some early results already emerging.\u003C\/p\u003E\u003Cp\u003ETo make a contribution in this climate, an antibody will need to have a strong edge over its competition. \u2018If one group\u2019s antibody turns out to be 10 times more potent than the next best, you might have to produce far less of it for an effective therapy, reducing the manufacturing burden,\u2019 explained Dr Murrell. He added, \u2018Since the potency of the antibodies discovered is at least partly down to chance, it makes sense for many groups to be going after the same goal.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EBacterium\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EProfessor Luis Serrano from the Centre for Genomic Regulation (CRG) in Spain leads another team engaged in the race against Covid-19. His lab is both supporting global vaccine efforts and probing novel, non-vaccine mechanisms to limit the death toll.\u003C\/p\u003E\u003Cp\u003EUntil two months ago, Prof. Serrano was engaged in the \u003Ca href=\u0022https:\/\/cordis.europa.eu\/project\/id\/634942\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EMycoSynVac project\u003C\/a\u003E, which investigated ways to enlist cellular hosts to transport vaccines around the body. Cellular hosts (known in the field of synthetic biology as chassis) hold great promise as low-cost, scalable and potentially game-changing systems for the targeted delivery of life-saving vaccines.\u003C\/p\u003E\u003Cp\u003EThe chosen chassis in Serrano\u2019s five-year project was a modified form of the bacterium \u003Cem\u003EMycoplasma pneumoniae\u003C\/em\u003E, which causes respiratory infections. By the project\u2019s conclusion, the researchers were able to show that Mycoplasma makes an excellent universal chassis \u2013 meaning all manner of vaccines can safely hitch a ride off it.\u003C\/p\u003E\u003Cp\u003EProf. Serrano is optimistic that a vaccine for Covid-19, when it arises, will be among the ingredients that can be safely delivered by his Mycoplasma chassis. The team is in the early stages of testing this hypothesis. Over the next month or so, they will insert synthetic copies of key coronavirus genes into bacterial cells, in the hope that those surface proteins belonging to the virus will trigger a protective immune response from the human body.\u003C\/p\u003E\u003Cp\u003EAs it is engineered from a bacterium that targets the lungs, the chassis may be capable of even more than vaccine transportation, according to Prof. Serrano. \u2018We think it can deliver therapeutic molecules directly to receptors in the lungs,\u2019 he said.\u003C\/p\u003E\u003Cp\u003EThese molecules would either counteract inflammation or stop the virus from binding to the alveoli (the cells through which oxygen flows from lungs to bloodstream) by blocking the viral cell receptors, he explains.\u003C\/p\u003E\u003Cp\u003EWith the virus blocked or lung damage repaired, a patient who is not responding to conventional treatments might be spared the worst symptoms of a Covid-19 infection, such as a devastating cytokine storm, where the body mounts a massive, and potentially deadly, immune response \u2013 an overreaction triggered by pneumonia.\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003ESpray\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u2018The idea is to create a spray to deliver our engineered bacteria directly to the lungs, where it will express locally what is needed \u2013 the active molecules \u2013 and later it will be washed away naturally,\u2019 explained Prof. Serrano.\u003C\/p\u003E\u003Cp\u003EHe added: \u2018There are clear advantages to this direct approach. If you apply a drug systemically (affecting the whole body), it might be beneficial where it\u2019s needed but it might also have dangerous effects on other tissue.\u2019\u003C\/p\u003E\u003Cp\u003EPrice is another major benefit to recruiting bacteria to deliver life-saving medications. Producing therapeutic molecules synthetically is expensive. For a fraction of the cost, a host cell can be cloned to produce vast populations of cells containing the same therapeutic molecules.\u003C\/p\u003E\u003Cp\u003EIn the labs of their spin-off company \u003Ca href=\u0022https:\/\/www.pulmobio.com\/\u0022 target=\u0022_blank\u0022 rel=\u0022noopener noreferrer\u0022\u003EPulmobiotics\u003C\/a\u003E, Prof. Serrano\u2019s team is exposing coronavirus proteins to molecules with known anti-inflammatory qualities, to test the molecules\u2019 effectiveness against the virus. They are also engineering mutations of these molecules, hoping to increase the affinity between molecule and human receptor proteins. Data from these experiments is expected by mid-summer.\u003C\/p\u003E\u003Cp\u003EProf Serrano is hopeful that his research will yield positive results, however these may not come in time to save lives during the current outbreak. \u2018By the time we get (regulatory) approval, the Covid situation may have been resolved,\u2019 he said. \u2018But this research will open the way for future therapies during future pandemics.\u2019\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThe research in this article was funded by the EU. If you liked this article, please consider sharing it on social media.\u003C\/em\u003E\u003C\/p\u003E\u003C\/textarea\u003E\n\u003C\/div\u003E\n\n \u003Cdiv id=\u0022edit-body-content--description\u0022 class=\u0022ecl-help-block description\u0022\u003E\n Please copy the above code and embed it onto your website to republish.\n \u003C\/div\u003E\n \u003C\/div\u003E\n\u003Cinput autocomplete=\u0022off\u0022 data-drupal-selector=\u0022form-5r-op8s4623lftuqma4y5d4hch-om1lbil0dogw6nhu\u0022 type=\u0022hidden\u0022 name=\u0022form_build_id\u0022 value=\u0022form-5r_op8S4623LFtUqMa4Y5D4HCH_OM1lbIL0dOgw6NhU\u0022 \/\u003E\n\u003Cinput data-drupal-selector=\u0022edit-modal-form-example-modal-form\u0022 type=\u0022hidden\u0022 name=\u0022form_id\u0022 value=\u0022modal_form_example_modal_form\u0022 \/\u003E\n\u003C\/form\u003E\n\u003C\/div\u003E","dialogOptions":{"width":"800","modal":true,"title":"Republish this content"}}]